Multiple small molecular compounds (e.g., salinomycin, prodigiosin, silibinin, rottlerin, gigantol, and CDDO-Me) have been shown to inhibit the Wnt/β-catenin pathway and growth in breast cancer cells by acting on LRP6 [24, 33–37]. This evidence concerns the gene LRP6 and breast carcinoma.